Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937918 | 0.82 | CYP1A2 (0.53) | MAPTALDH1A1L3MBTL1TRPV1DRD4 | |
| SCHEMBL1370146 | 0.79 | LMNA (0.59) | LMNATRPV1HSD11B1 | |
| SCHEMBL8299219 | 0.79 | LMNA (0.59) | LMNATRPV1HSD11B1 | |
| SCHEMBL1369593 | 0.79 | EPHX2 (0.66) | LMNAMAPTHSD11B1EPHX2 | |
| SCHEMBL29392900 | 0.78 | MAPT (0.45) | MAPTALDH1A1L3MBTL1TRPV1DRD4 | |
| SCHEMBL1725284 | 0.77 | CYP1A2 (0.56) | LMNAALDH1A1DRD4CYP1A2CYP2C9 | |
| SCHEMBL10964078 | 0.77 | HRH4 (0.53) | MAPTDRD4MAPK1 | |
| SCHEMBL1758382 | 0.77 | EPHX2 (0.64) | ALDH1A1EPHX2 | |
| SCHEMBL13271105 | 0.77 | LMNA (0.56) | LMNAHSD11B1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10964762 | 0.77 | ALDH1A1 (0.50) | LMNAMAPTALDH1A1L3MBTL1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680118-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680118-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2091936-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA LP (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2091936-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA LP (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8389549-B2 | Substituted pyridines useful for treating pain | PURDUE PHARMA L.P. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389549-B2 | Substituted pyridines useful for treating pain | PURDUE PHARMA L.P. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389549-B2 | Substituted pyridines useful for treating pain | PURDUE PHARMA L.P. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130012541-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012541-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2479173-A1 | Therapeutic agents useful for treating pain | Purdue Pharma LP (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2091936-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | Purdue Pharma LP (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-2060260-A1 | Therapeutic agents useful for treating pain | Euro-Celtique S.A. (LU) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008133973-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008133973-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1862458-B1 | Therapeutic agents useful for treating pain | EURO CELTIQUE SA (LU) | 2008-11-05 | — | — | EP | disclosed |
| EP-1862458-A2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-12-05 | — | — | EP | disclosed |
| EP-1631285-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2007-08-08 | — | — | EP | disclosed |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-01 | — | — | US | disclosed |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-01 | — | — | US | disclosed |
| WO-2005004866-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE, S.A. (LU) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027159-A1 | Therapeutic agents useful for treating pain | ARRB1, FPR1, OPRL1 | LMNA 4683/4885MAPT 2150/4885ALDH1A1 875/4885 |
| US-20130012541-A1 | Therapeutic Agents Useful for Treating Pain | ARRB1, FPR1, OPRL1 | LMNA 4683/4885MAPT 2150/4885ALDH1A1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.